Literature DB >> 22743087

Effects on polo-like kinase 1 polo-box domain binding affinities of peptides incurred by structural variation at the phosphoamino acid position.

Wenjian Qian1, Jung-Eun Park, Fa Liu, Kyung S Lee, Terrence R Burke.   

Abstract

Protein-protein interactions (PPIs) mediated by the polo-box domain (PBD) of n class="Gene">polo-like kinase 1 (n class="Gene">Plk1) serve important roles in cell proliferation. Critical elements in the high affinity recognition of peptides and proteins by PBD are derived from pThr/pSer-residues in the binding ligands. However, there has been little examination of pThr/pSer mimetics within a PBD context. Our current paper compares the abilities of a variety of amino acid residues and derivatives to serve as pThr/pSer replacements by exploring the role of methyl functionality at the pThr β-position and by replacing the phosphoryl group by phosphonic acid, sulfonic acid and carboxylic acids. This work sheds new light on structure activity relationships for PBD recognition of phosphoamino acid mimetics. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22743087      PMCID: PMC3462889          DOI: 10.1016/j.bmc.2012.05.036

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  63 in total

Review 1.  Polo-like kinases, an introduction.

Authors:  Wei Dai
Journal:  Oncogene       Date:  2005-01-10       Impact factor: 9.867

Review 2.  Principles of protein-protein interactions: what are the preferred ways for proteins to interact?

Authors:  Ozlem Keskin; Attila Gursoy; Buyong Ma; Ruth Nussinov
Journal:  Chem Rev       Date:  2008-03-21       Impact factor: 60.622

Review 3.  Polo-like kinases: conservation and divergence in their functions and regulation.

Authors:  Vincent Archambault; David M Glover
Journal:  Nat Rev Mol Cell Biol       Date:  2009-04       Impact factor: 94.444

4.  Context-based identification of protein-protein interfaces and "hot-spot" residues.

Authors:  Tim Geppert; Benjamin Hoy; Silja Wessler; Gisbert Schneider
Journal:  Chem Biol       Date:  2011-03-25

5.  ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

Authors:  Kiranmai Gumireddy; M V Ramana Reddy; Stephen C Cosenza; R Boominathan; R Boomi Nathan; Stacey J Baker; Nabisa Papathi; Jiandong Jiang; James Holland; E Premkumar Reddy
Journal:  Cancer Cell       Date:  2005-03       Impact factor: 31.743

6.  Ligands for the tyrosine kinase p56lck SH2 domain: discovery of potent dipeptide derivatives with monocharged, nonhydrolyzable phosphate replacements.

Authors:  P L Beaulieu; D R Cameron; J M Ferland; J Gauthier; E Ghiro; J Gillard; V Gorys; M Poirier; J Rancourt; D Wernic; M Llinas-Brunet; R Betageri; M Cardozo; E R Hickey; R Ingraham; S Jakes; A Kabcenell; T Kirrane; S Lukas; U Patel; J Proudfoot; R Sharma; L Tong; N Moss
Journal:  J Med Chem       Date:  1999-05-20       Impact factor: 7.446

7.  The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.

Authors:  Péter Lénárt; Mark Petronczki; Martin Steegmaier; Barbara Di Fiore; Jesse J Lipp; Matthias Hoffmann; Wolfgang J Rettig; Norbert Kraut; Jan-Michael Peters
Journal:  Curr Biol       Date:  2007-02-08       Impact factor: 10.834

Review 8.  Polo-like kinases and oncogenesis.

Authors:  Frank Eckerdt; Juping Yuan; Klaus Strebhardt
Journal:  Oncogene       Date:  2005-01-10       Impact factor: 9.867

9.  Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1.

Authors:  Sang-Moon Yun; Tinoush Moulaei; Dan Lim; Jeong K Bang; Jung-Eun Park; Shilpa R Shenoy; Fa Liu; Young H Kang; Chenzhong Liao; Nak-Kyun Soung; Sunhee Lee; Do-Young Yoon; Yoongho Lim; Dong-Hee Lee; Akira Otaka; Ettore Appella; James B McMahon; Marc C Nicklaus; Terrence R Burke; Michael B Yaffe; Alexander Wlodawer; Kyung S Lee
Journal:  Nat Struct Mol Biol       Date:  2009-07-13       Impact factor: 15.369

10.  A MEK-independent role for CRAF in mitosis and tumor progression.

Authors:  Ainhoa Mielgo; Laetitia Seguin; Miller Huang; Maria Fernanda Camargo; Sudarshan Anand; Aleksandra Franovic; Sara M Weis; Sunil J Advani; Eric A Murphy; David A Cheresh
Journal:  Nat Med       Date:  2011-11-13       Impact factor: 53.440

View more
  13 in total

Review 1.  Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.

Authors:  Kyung S Lee; Terrence R Burke; Jung-Eun Park; Jeong K Bang; Eunhye Lee
Journal:  Trends Pharmacol Sci       Date:  2015-10-17       Impact factor: 14.819

2.  Peptide-based inhibitors of Plk1 polo-box domain containing mono-anionic phosphothreonine esters and their pivaloyloxymethyl prodrugs.

Authors:  Wen-Jian Qian; Jung-Eun Park; Dan Lim; Suk-Youl Park; Ki-Won Lee; Michael B Yaffe; Kyung S Lee; Terrence R Burke
Journal:  Chem Biol       Date:  2013-10-10

3.  Histidine N(τ)-cyclized macrocycles as a new genre of polo-like kinase 1 polo-box domain-binding inhibitors.

Authors:  David Hymel; Robert A Grant; Kohei Tsuji; Michael B Yaffe; Terrence R Burke
Journal:  Bioorg Med Chem Lett       Date:  2018-08-19       Impact factor: 2.823

4.  Phosphatase-Stable Phosphoamino Acid Mimetics That Enhance Binding Affinities with the Polo-Box Domain of Polo-like Kinase 1.

Authors:  David Hymel; Terrence R Burke
Journal:  ChemMedChem       Date:  2017-01-09       Impact factor: 3.466

5.  Application of oxime-diversification to optimize ligand interactions within a cryptic pocket of the polo-like kinase 1 polo-box domain.

Authors:  Xue Zhi Zhao; David Hymel; Terrence R Burke
Journal:  Bioorg Med Chem Lett       Date:  2016-09-02       Impact factor: 2.823

6.  Non-proteinogenic amino acids in the pThr-2 position of a pentamer peptide that confer high binding affinity for the polo box domain (PBD) of polo-like kinase 1 (Plk1).

Authors:  Wen-Jian Qian; Jung-Eun Park; Kyung S Lee; Terrence R Burke
Journal:  Bioorg Med Chem Lett       Date:  2012-10-27       Impact factor: 2.823

7.  Mono-anionic phosphopeptides produced by unexpected histidine alkylation exhibit high Plk1 polo-box domain-binding affinities and enhanced antiproliferative effects in HeLa cells.

Authors:  Wen-Jian Qian; Jung-Eun Park; Dan Lim; Christopher C Lai; James A Kelley; Suk-Youl Park; Ki Won Lee; Michael B Yaffe; Kyung S Lee; Terrence R Burke
Journal:  Biopolymers       Date:  2014-11       Impact factor: 2.505

8.  Exploring the binding nature of pyrrolidine pocket-dependent interactions in the polo-box domain of polo-like kinase 1.

Authors:  Ravichandran N Murugan; Mija Ahn; Woo Cheol Lee; Hye-Yeon Kim; Jung Hyun Song; Chaejoon Cheong; Eunha Hwang; Ji-Hyung Seo; Song Yub Shin; Sun Ho Choi; Jung-Eun Park; Jeong Kyu Bang
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

9.  Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1.

Authors:  Ganipisetti Srinivasrao; Jung-Eun Park; Sungmin Kim; Mija Ahn; Chaejoon Cheong; Ky-Youb Nam; Pethaiah Gunasekaran; Eunha Hwang; Nam-Hyung Kim; Song Yub Shin; Kyung S Lee; Eunkyung Ryu; Jeong Kyu Bang
Journal:  PLoS One       Date:  2014-09-11       Impact factor: 3.240

10.  Uncoupling the Folding-Function Paradigm of Lytic Peptides to Deliver Impermeable Inhibitors of Intracellular Protein-Protein Interactions.

Authors:  Stephen E Miller; Kohei Tsuji; Rachel P M Abrams; Terrence R Burke; Joel P Schneider
Journal:  J Am Chem Soc       Date:  2020-11-11       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.